...
首页> 外文期刊>Journal of Thoracic Disease >Pleural mesothelial cells in pleural and lung diseases
【24h】

Pleural mesothelial cells in pleural and lung diseases

机译:胸膜间皮细胞与胸膜和肺部疾病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

During development, the mesoderm maintains a complex relationship with the developing endoderm giving rise to the mature lung. Pleural mesothelial cells (PMCs) derived from the mesoderm play a key role during the development of the lung. The pleural mesothelium differentiates to give rise to the endothelium and smooth muscle cells via epithelial-to-mesenchymal transition (EMT). An aberrant recapitulation of such developmental pathways can play an important role in the pathogenesis of disease processes such as idiopathic pulmonary fibrosis (IPF). The PMC is the central component of the immune responses of the pleura. When exposed to noxious stimuli, it demonstrates innate immune responses such as Toll-like receptor (TLR) recognition of pathogen associated molecular patterns as well as causes the release of several cytokines to activate adaptive immune responses. Development of pleural effusions occurs due to an imbalance in the dynamic interaction between junctional proteins, n-cadherin and β-catenin, and phosphorylation of adherens junctions between PMCs, which is caused in part by vascular endothelial growth factor (VEGF) released by PMCs. PMCs play an important role in defense mechanisms against bacterial and mycobacterial pleural infections, and in pathogenesis of malignant pleural effusion, asbestos related pleural disease and malignant pleural mesothelioma. PMCs also play a key role in the resolution of inflammation, which can occur with or without fibrosis. Fibrosis occurs as a result of disordered fibrin turnover and due to the effects of cytokines such as transforming growth factor-β, platelet-derived growth factor (PDGF), and basic fibroblast growth factor; which are released by PMCs. Recent studies have demonstrated a role for PMCs in the pathogenesis of IPF suggesting their potential as a cellular biomarker of disease activity and as a possible therapeutic target. Pleural-based therapies targeting PMCs for treatment of IPF and other lung diseases need further exploration.
机译:在发育过程中,中胚层与发育中的内胚层保持复杂的关系,从而形成成熟的肺。源自中胚层的胸膜间皮细胞(PMC)在肺部发育过程中起关键作用。胸膜间皮细胞通过上皮-间充质转化(EMT)分化为内皮细胞和平滑肌细胞。这种发育途径的异常概括可在疾病过程如特发性肺纤维化(IPF)的发病机理中起重要作用。 PMC是胸膜免疫反应的重要组成部分。当暴露于有害刺激下时,它表现出先天性免疫反应,例如与病原体相关的分子模式的Toll样受体(TLR)识别,并引起多种细胞因子的释放,从而激活适应性免疫反应。胸腔积液的发生是由于连接蛋白,n-钙黏着蛋白和β-连环蛋白之间的动态相互作用不平衡以及PMC之间粘附连接的磷酸化引起的,这部分是由PMC释放的血管内皮生长因子(VEGF)引起的。 PMC在抵抗细菌性和分枝杆菌性胸膜感染的防御机制以及恶性胸腔积液,石棉相关性胸膜疾病和恶性胸膜间皮瘤的发病机理中起着重要作用。 PMCs在炎症的消退中也起着关键作用,炎症可以发生或不发生纤维化。纤维化是由于纤维蛋白周转紊乱和细胞因子(如转化生长因子-β,血小板衍生生长因子(PDGF)和碱性成纤维细胞生长因子)的作用而发生的。由PMC发布。最近的研究表明,PMC在IPF的发病机理中发挥了作用,表明它们作为疾病活动的细胞生物标志物和可能的治疗靶标的潜力。针对PMC的以胸膜为基础的治疗IPF和其他肺部疾病的疗法需要进一步探索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号